The U.S. Centers for Medicare and Medicaid Services (CMS) has finalized its previously announced proposal to expand Medicare coverage of MRI with implanted pacemakers.
The July 7 final national coverage determination (NCD) follows an April decision by CMS that stipulates that the agency will pay for MRI scans of certain pacemakers that can be used in an MRI environment according to guidelines from the U.S. Food and Drug Administration (FDA).
The latest communiqué from CMS is good news for Medtronic. The company's Revo MRI SureScan pacing system was cleared by the FDA in February for use with certain MRI exams. It is the only pacemaker or implantable cardioverter defibrillator device with the agency's nod for use in the MRI environment.
